iRGD peptide 1 TFA |
Catalog No.GC60204 |
iRGD peptide 1 TFA est le prototype de peptide pénétrant dans les tissus, spécifique À la tumeur, qui délivre des médicaments profondément dans le tissu tumoral extravasculaire. iRGD peptide 1 TFA a une activité anti-métastatique.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
iRGD peptide 1 TFA is the prototypic tumor-specific tissue-penetrating peptide, which delivers drugs deep into extravascular tumor tissue. iRGD peptide 1 TFA has anti-metastatic activity[1].
iRGD peptide 1 (iRGD) inhibits migration of tumor cells and caused chemorepulsion in vitro in a CendR- and NRP-1-dependent manner. iRGD peptide 1 induces dramatic collapse of cellular processes and partial cell detachment, resulting in the repellent activity. These effects are prominently displayed when the cells are seeded on fibronectin, suggesting a role of CendR in functional regulation of integrins[1].
iRGD peptide 1 (amino acid sequence: CRGDKGPDC; 4 μmol/kg; intravenous injection; every other day; for 21 days) potently inhibits spontaneous metastasis in mice[1].
[1]. Kazuki N Sugahara, et al. Tumor-penetrating iRGD Peptide Inhibits Metastasis. Mol Cancer Ther. 2015 Jan;14(1):120-8.
Average Rating: 5
(Based on Reviews and 2 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *